Immunotherapy, pembrolizumab, is active against mucosal melanoma tumors – Science Daily
Immunotherapy, pembrolizumab, is active against mucosal melanoma tumorsScience DailyClinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-… Continue reading
